Analyst Sees Promise in Pfizer Inc. Lung Cancer Drug, Bets on Approval

A potential treatment for advanced lung cancer from Pfizer Inc. has about an 80 percent chance of receiving Food and Drug Administration approval this year, according to a Credit Suisse analyst. The world's largest drugmaker presented research earlier this month on crizotinib that shows the treatment appears to double survival over standard drugs against tumors with a certain genetic mutation. The FDA gave the drug a "Fast Track designation" last December, and the New York drugmaker was able to start submitting batches of data in January, instead of waiting until all studies are completed.

Back to news